

Lactobacillus rhamnosus Bacteremia in an Immunocompromised Renal Transplant Patient

Selin Sendil¹, Isha Shrimanker¹, Qurat Mansoor¹, John Goldman², Vinod K. Nookala¹

1. Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, USA 2. Internal Medicine: Infectious Disease, UPMC Pinnacle, Harrisburg, USA

Corresponding author: Isha Shrimanker, ims18919@gmail.com

Abstract

Conventionally, Lactobacillus species are considered as low virulence organisms and rarely cause infection in immunocompetent individuals. However, it might be an opportunistic infection source in immunocompromised patients and can cause invasive serious infections. To our knowledge, there are only a handful of cases in the literature reporting primary bloodstream infection caused by Lactobacilli spp. in transplant recipients. Here, we report a case of a kidney transplant recipient with Lactobacillus rhamnosus bacteremia.

Categories: Infectious Disease, Nephrology, Transplantation

Keywords: bacteremia, lactobacillus rhamnosus, renal transplant

Introduction

Lactobacillus spp. are facultatively anaerobic, gram-positive non-spore-forming rods that are a part of the normal human commensal microbiota of the oral, gastrointestinal, and female genital tract [1]. Some Lactobacillus spp. are used in probiotic products for potential benefits related to fermentative properties with limited scientific evidence to support their use [2].

Conventionally, Lactobacillus spp. are deemed to be of low virulence; however, a number of publications point out potential harmful effects with their use ranging from gastrointestinal side effects to invasive systemic infections such as peritonitis, deep abdominal abscesses, and bacteremia [1,3,4]. In some reports from Europe, Lactobacillus rhamnosus (*L. rhamnosus*) was the most common species involved in Lactobacillus bacteremia [4]. We report a case of *L. rhamnosus* bacteremia in an elderly immunosuppressed male with multiple comorbidities.

Case Presentation

A 75-year-old male with end-stage renal disease secondary to type 2 diabetes mellitus who received deceased donor renal transplant in 2012 presented with worsening kidney function, altered mental status, severe septic shock, and respiratory failure. The patient was under maintenance immunosuppression with tacrolimus 3.5 mg twice daily, mycophenolate mofetil 180 mg twice daily, and prednisone 5 mg once daily. Past medical history was also significant for stroke (status post carotid angioplasty), coronary artery disease, and essential hypertension. He was transferred to the intensive care unit (ICU) from a long-term acute care facility (LTACH). At the LTACH facility, he was treated with oral vancomycin for *Clostridium difficile* (*C. difficile*) infection, along with intravenous vancomycin and meropenem for right heel osteomyelitis. Six months before the ICU admission, he was found to have acute tubular necrosis, proven by kidney biopsy, and receiving intermittent hemodialysis.

Received 01/27/2020

Review began 01/27/2020

Review ended 02/03/2020

Published 02/05/2020

© Copyright 2020

Sendil et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Sendil S, Shrimanker I, Mansoor Q, et al. (February 05, 2020) Lactobacillus rhamnosus Bacteremia in an Immunocompromised Renal Transplant Patient. Cureus 12(2): e6887. DOI 10.7759/cureus.6887

On arrival to the ICU, his pulse was 118 beats per minute, blood pressure 119/69 mmHg, respiratory rate of 12 breaths per minute, and oxygen saturation of 100% on room air. On physical exam, he had bilateral pedal edema. Laboratory investigations revealed hemoglobin of 7.9 g/dl, potassium of 7.1, blood urea nitrogen 60 mg/dl, and creatinine 1.91 mg/dl. Urine analysis revealed leukocyte esterase +1, red blood cells 16-30/hpf, white blood cells 6-10/hpf, and urine bacteria +1. The patient was in severe septic shock requiring five vasopressors and initially treated with broad-spectrum antibiotics (intravenous vancomycin, cefepime, and metronidazole). Both blood culture bottles grew *L. rhamnosus*, and anti-biotherapy was narrowed to ampicillin alone.

The identification of *L. rhamnosus* was performed by the 16S rDNA sequence analysis by the collaborating laboratory. CT of the abdomen and pelvis was negative for a source of bacteremia. Repeat blood cultures grew yeast. Anti-biotherapy broadened to micafungin, vancomycin, and piperacillin/tazobactam. While he was in the LTACH facility, his kidney function progressively worsened, and he required emergent hemodialysis. During his ICU stay, he was on continuous renal replacement therapy intermittently. His overall clinical status improved, and the vasopressors were weaned off. He was successfully extubated. However, he remained encephalopathic. His family decided to continue with comfort measures only and he passed away in a few days.

Discussion

Lactobacillus spp. has been considered an opportunistic pathogen in immunocompromised patients, and it has the propensity to cause invasive infections such as bacteremia, abscess, and endocarditis. Other reported risk factors include intravenous catheters, prior hospitalization or surgery, and broad-spectrum antibiotic use [4]. In the study by Salminen et al., overall mortality was found to be 26% at one month and 48% at one year [4]. Naqvi et al. reported a case of fatal *L. rhamnosus* endocarditis involving a young patient with a history of complicated cirrhosis and prior *C. difficile* colitis [5]. The patients with loss of integrity of the intestinal mucosal barrier are also at increased risk; hence, several occurrences of *Lactobacillus* bacteremia have been reported in patients with ulcerative colitis [6]. Gut translocation and systemic dissemination of organisms may be the underlying pathogenesis for invasive infections in immunocompromised patients [7]. *L. rhamnosus* strains have been found to induce platelet aggregations, have a modified exopolysaccharide cluster, and form strong biofilms [8,9].

Lactobacillus bacteremia has been reported in patients with acute myeloid leukemia, large granular lymphocytic leukemia, and in transplant recipients [10]. Recurrent *Lactobacillus* spp. bacteremia with chronic lymphocytic leukemia has been reported. The *Lactobacilli* isolated from blood cultures were susceptible to penicillin and gentamicin, and the patient was treated with this regimen. The authors concluded that despite intermittent fever-free periods and negative blood cultures after treatment, successful eradication of the underlying source is doubtful given his recurrent bacteremia. Therefore, the patient was ultimately placed on life-long oral amoxicillin-clavulanate therapy for prophylaxis [11].

Our patient received a renal transplant in 2013 and was under maintenance immunosuppression regimen with tacrolimus, mycophenolate mofetil, and prednisone. The review of our patient's chart revealed that he had been taking probiotic supplements containing *Lactobacillus acidophilus* and *Lactobacillus bulgaris* for five months before his transfer to the ICU. Probiotic pills were not sent for testing due to unavailability; however, colonization by probiotic use long after consumption stopped is highly questionable. Also, these strains are different from those detected in blood cultures. To our knowledge, there are only two more case reports in the literature reporting primary bloodstream infection caused by *Lactobacilli* spp. in a kidney transplant recipient [12,13]. Vanichanan et al. reported a 60-year-old renal transplant recipient who developed an intra-abdominal abscess which grew a

carbapenem-resistant *Lactobacillus casei* (*L. casei*), with an uneventful follow-up course for four years. He had been taking an over-the-counter probiotic for six months, until two months before presentation when he developed abdominal discomfort due to enlarging native kidneys. He underwent bilateral native nephrectomy and was discharged home. One week later, he returned to the hospital in septic shock and respiratory failure. The culture of the perihepatic fluid grew *L. casei*. In addition, the probiotic supplement taken by the patient also grew a similar organism raising the concern of probiotic-associated infection in immunocompromised individual [13].

The treatment of invasive, severe, or recurrent *Lactobacillus* infections can be challenging. Many strains of *Lactobacillus*, including *L. rhamnosus*, are intrinsically resistant to vancomycin. Resistance to ciprofloxacin, tetracycline, meropenem, metronidazole, and sulfonamides has been reported, with some isolates exhibiting intermediate resistance to linezolid [14].

In recent years, the use of probiotics has increased worldwide for the treatment of infantile and adult diarrhea, *C. difficile* diarrhea, irritable bowel syndrome, allergy (can be elaborated here), prevention of urogenital tract infections, inflammatory bowel disease, and candidal vaginitis. Bafeta et al. gathered data from several published trials to examine how harms-related information is reported in publications of randomized controlled trials (RCTs, n=384) of probiotics, prebiotics, and synbiotics. They concluded that harms reporting in published reports of RCTs assessing probiotics, prebiotics, and synbiotics are often lacking or inadequate, and it cannot be broadly concluded that these interventions are safe without reporting safety data [15]. In an epidemiological study of *Lactobacillus* bacteremia in Finland, the researchers did not find any correlation between the increased probiotic use of *L. rhamnosus* GG (ATCC 53103) and the incidence of *Lactobacillus* bacteremia during 1990-2000 [2]. The FDA suggested immunosuppression, structural heart disease, inpatient, pregnancy, and potential for translocation of probiotic across the bowel wall to be potentially at risk for adverse events in probiotic clinical trials.

Conclusions

Mostly deemed as low-virulence or concomitant, *Lactobacillus* spp. might be an opportunistic pathogen in immunocompromised, transplant patients and might be related to increased mortality.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. UPMC Pinnacle Institutional Review Board issued approval NA. As long as no personal identifiable information is used and all information presented for publication is de-identified per HIPAA regulations, this research is exempt under 45 CFR 46.101 (b) (4) and does not need to be submitted to the IRB for review and approval. . **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Tena D, Martinez NM, Losa C, Fernandez C, Medina MJ, Saez-Nieto JA: Acute acalculous

- cholecystitis complicated with peritonitis caused by *Lactobacillus plantarum*. *Diagn Microbiol Infect Dis*. 2013, 76:510-512. [10.1016/j.diagmicrobio.2013.03.018](https://doi.org/10.1016/j.diagmicrobio.2013.03.018)
2. Salminen MK, Tynkkynen S, Rautelin H, et al.: *Lactobacillus* bacteremia during a rapid increase in probiotic use of *Lactobacillus rhamnosus* GG in Finland. *Clin Infect Dis*. 2002, 35:1155-1160. [10.1086/342912](https://doi.org/10.1086/342912)
 3. Lu PL, Hsueh PR, Chen YC, Teng LJ, Chang SC, Luh KT: Clones of *Lactobacillus casei* and *Torulopsis glabrata* associated with recurrent abdominal wall abscess. *J Formos Med Assoc*. 1999, 98:356-360.
 4. Salminen MK, Rautelin H, Tynkkynen S, et al.: *Lactobacillus* bacteremia, clinical significance, and patient outcome, with special focus on probiotic *L. rhamnosus* GG. *Clin Infect Dis*. 2004, 38:62-69. [10.1086/380455](https://doi.org/10.1086/380455)
 5. Naqvi SSB, Nagendra V, Hofmeyr A: Probiotic related *Lactobacillus rhamnosus* endocarditis in a patient with liver cirrhosis. *IDCases*. 2018, 13:e00439. [10.1016/j.idcr.2018.e00439](https://doi.org/10.1016/j.idcr.2018.e00439)
 6. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA: *Lactobacillus* bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. *J Clin Gastroenterol*. 2013, 47:437-439. [10.1097/MCG.0b013e318279abf0](https://doi.org/10.1097/MCG.0b013e318279abf0)
 7. Rautio M, Jousimies-Somer H, Kauma H, et al.: Liver abscess due to a *Lactobacillus rhamnosus* strain indistinguishable from *L. rhamnosus* strain GG. *Clin Infect Dis*. 1999, 28:1159-1160. [10.1086/514766](https://doi.org/10.1086/514766)
 8. Nissilä E, Douillard FP, Ritari J, et al.: Genotypic and phenotypic diversity of *Lactobacillus rhamnosus* clinical isolates, their comparison with strain GG and their recognition by complement system. *PLoS One*. 2017, 12:e0176739. [10.1371/journal.pone.0176739](https://doi.org/10.1371/journal.pone.0176739)
 9. Nadkarni MA, Chen Z, Wilkins MR, Hunter N: Comparative genome analysis of *Lactobacillus rhamnosus* clinical isolates from initial stages of dental pulp infection: identification of a new exopolysaccharide cluster. *PLoS One*. 2014, 9:e90643. [10.1371/journal.pone.0090643](https://doi.org/10.1371/journal.pone.0090643)
 10. Cohen SA, Woodfield MC, Boyle N, Stednick Z, Boeckh M, Pergam SA: Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations. *Transpl Infect Dis*. 2016, 18:699-705. [10.1111/tid.12587](https://doi.org/10.1111/tid.12587)
 11. Ambesh P, Stroud S, Franzova E, et al.: Recurrent *Lactobacillus* bacteremia in a patient with leukemia. *J Investig Med High Impact Case Rep*. 2017, 5:2324709617744233. [10.1177/2324709617744233](https://doi.org/10.1177/2324709617744233)
 12. Falci DR, Rigatto MH, Cantarelli VV, Zavascki AP: *Lactobacillus rhamnosus* bacteremia in a kidney transplant recipient. *Transpl Infect Dis*. 2015, 17:610-612. [10.1111/tid.12410](https://doi.org/10.1111/tid.12410)
 13. Vanichanan J, Chavez V, Wanger A, De Golovine AM, Vigil KJ: Carbapenem-resistant *Lactobacillus* intra-abdominal infection in a renal transplant recipient with a history of probiotic consumption. *Infection*. 2016, 44:793-796. [10.1007/s15010-016-0903-1](https://doi.org/10.1007/s15010-016-0903-1)
 14. Danielsen M, Wind A, Leisner JJ, Arpi M: Antimicrobial susceptibility of human blood culture isolates of *Lactobacillus* spp. *Eur J Clin Microbiol Infect Dis*. 2007, 26:287-289. [10.1007/s10096-007-0274-8](https://doi.org/10.1007/s10096-007-0274-8)
 15. Bafeta A, Koh M, Riveros C, Ravaud P: Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. *Ann Intern Med*. 2018, 169:240-247. [10.7326/m18-0343](https://doi.org/10.7326/m18-0343)